Hsbc Holdings PLC Has $18.91 Million Stock Position in Moderna, Inc. $MRNA

Hsbc Holdings PLC lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 14.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 638,370 shares of the company’s stock after selling 107,077 shares during the quarter. Hsbc Holdings PLC’s holdings in Moderna were worth $18,911,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. New Mexico Educational Retirement Board lifted its holdings in Moderna by 1.9% in the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock valued at $463,000 after buying an additional 300 shares during the period. Cromwell Holdings LLC increased its holdings in Moderna by 39.7% in the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Moderna by 5.4% during the 4th quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock valued at $200,000 after acquiring an additional 348 shares during the period. Empowered Funds LLC raised its holdings in shares of Moderna by 2.6% during the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock valued at $405,000 after purchasing an additional 353 shares during the period. Finally, Deseret Mutual Benefit Administrators boosted its holdings in Moderna by 16.9% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock worth $78,000 after acquiring an additional 382 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the transaction, the insider owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the sale, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,088 shares of company stock valued at $6,193,713 over the last three months. Insiders own 10.80% of the company’s stock.

Moderna Stock Performance

Shares of MRNA opened at $79.77 on Wednesday. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $85.60. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. The stock’s fifty day moving average price is $54.66 and its two-hundred day moving average price is $48.93. The firm has a market cap of $31.65 billion, a PE ratio of -9.79 and a beta of 0.94.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The business had revenue of $389.00 million for the quarter, compared to analysts’ expectations of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The business’s quarterly revenue was up 260.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.52) earnings per share. On average, equities research analysts forecast that Moderna, Inc. will post -6.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MRNA. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a report on Thursday, June 18th. UBS Group reiterated a “neutral” rating on shares of Moderna in a report on Tuesday, May 26th. Bank of America boosted their price target on shares of Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a report on Tuesday. Piper Sandler upped their price objective on shares of Moderna from $69.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, June 26th. Finally, Royal Bank Of Canada increased their price objective on shares of Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $37.87.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.